SCHEMBL2174682

SCHEMBL2174682

CC(C)(C)OC(=O)N(Cc1cc(C(=O)O)ccc1F)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.43
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
EPHX2 P34913 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
PTK2B Q14289 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
GRM2 Q14416 1/20 0.38
RIPK1 Q13546 2/20 0.37
LPAR1 Q92633 2/20 0.37
LPAR5 Q9H1C0 2/20 0.37
TAS2R14 Q9NYV8 2/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941296 0.86 CDC25B (0.42) LMNAHTTRAB9AGRM2HDAC3
SCHEMBL12406956 0.84 CA12 (0.43) LMNAMEN1KMT2AHDAC3HDAC1
SCHEMBL6392687 0.82 ACE2 (0.36) EPHX2NR1H4KMT2AGRM2HDAC3
SCHEMBL6675419 0.82 GRM2 (0.40) GRM2RIPK1HTR2AHTR2CSLC6A4
SCHEMBL6950389 0.82 POLB (0.49) LMNA
SCHEMBL6542485 0.79 ALDH1A1 (0.43) MRGPRX4LPAR1LPAR5TAS2R14ALDH1A1
SCHEMBL20649292 0.78 CREBBP (0.36) MRGPRX4EPHX2NR1H4TRPM8HTR2C
SCHEMBL6676629 0.77 ALDH1A1 (0.45) LMNAHTTRAB9AMEN1KMT2A
SCHEMBL15862233 0.77 HTR2C (0.41) EPHX2NR1H4MEN1KMT2AATM
SCHEMBL18300233 0.76 TMPRSS15 (0.40) GRM2RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 EP disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
EP-2050446-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 MRGPRX4 454/4885LMNA 4123/4885MAPK1 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.